Navigation Links
Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
Date:6/2/2008

- 50% of All Evaluable Patients in Phase I Study Receiving Combination of Bavituximab Plus Chemotherapy Achieved Objective Tumor Response or Stable

Disease - - 100% of Evaluable Patients to Date in Ongoing Phase II Breast Cancer

Study Showing Objective Tumor Response or Stable Disease -

CHICAGO and TUSTIN, Calif., June 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase I data indicated that half of evaluable patients in the trial achieved objective tumor response or stable disease after eight weeks of dosing. The Phase I study results also showed that the safety profile of bavituximab and chemotherapy appeared consistent with chemotherapy alone and that the pharmacokinetic properties of bavituximab were not impacted by co- administration with conventional chemotherapies.

Separately, Peregrine reported an update from its ongoing Phase II trial evaluating bavituximab plus docetaxel in advanced breast cancer. Enrollment of an initial group of 15 patients in the two-stage Phase II study was recently completed. Of the 11 evaluable patients to date, none have experienced any measureable tumor growth or disease progression, with five of the 11 evaluable patients achieving a partial tumor response. All enrolled patients are continuing to receive treatment and are being evaluated regularly for tumor response according to RECIST criteria. The primary objective of the multi-center, open
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
2. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
9. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
10. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
11. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... METTLER TOLEDO’s newly improved XS balance line includes ... well as a dual range microbalance . As ... weighing pan delivers results up to twice as fast, ... design details mean users no longer need to suffer ... in front of the balance. Barbara Bienlein, medical specialist ...
(Date:10/1/2014)... Mass. , Oct. 1, 2014  Pressure BioSciences, ... leader in the development and sale of high pressure-based ... today announced it has been invited to present at ... Warsaw , Poland.  The Conference will ... 2, 2014.  Mr. Richard T. Schumacher , President ...
(Date:10/1/2014)... , Oct. 1, 2014  Spherix Incorporated (Nasdaq: ... fostering and monetization of intellectual property, announced today ... VTech and Uniden in the U.S. District Court ... has been rescheduled for November 10, ... 2, 2014.  The Court Order setting the Markman ...
(Date:10/1/2014)... CA (PRWEB) October 01, 2014 As the ... leaves no room for doubt that this century would mark ... in the field of medicine science. The fact that the ... is not unknown to the scientific community. Almost half of ... and therefore can be prevented with medical care and intervention. ...
Breaking Biology Technology:METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 2Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 4Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 3
... SAN FRANCISCO, Oct. 26 MedImmune, Inc. today ... Academy of Pediatrics (AAP),2007 National Conference & Exhibition, ... the prevention of respiratory syncytial virus (RSV), a,leading ... pleased to present data that provide key insights ...
... Healthcare Services,Inc. (NYSE: AHS ), the nation,s ... presentation on Tuesday, November 6, 2007 at 12:45 ... Annual Healthcare Conference,taking place at the Waldorf-Astoria Hotel ... ) Susan R. Nowakowski, President and Chief ...
... Required for Integra Merger, IRVINE, California, October 26 ... company, today reported that,less than 100,000 votes "FOR" are ... Holdings Corporation (NASDAQ: IART ),("Integra") pursuant to an ... 2007. Today,s special meeting of stockholders will remain ...
Cached Biology Technology:MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition 2MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition 3MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition 4MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition 5AMN Healthcare Services to Present at the CIBC World Markets 18th Annual Healthcare Conference 2IsoTis Reports Status of Merger Vote 2IsoTis Reports Status of Merger Vote 3IsoTis Reports Status of Merger Vote 4
(Date:9/30/2014)... salmon, and strawberries all have in common? Unlike ... chromosomes and are diploid, these organisms are all polyploid, ... watermelon and salmon have 3 and 4 sets of ... might seem surprising, in fact most plant species are ... a century ago, but only recently, with the development ...
(Date:9/30/2014)... The National Institutes of Health (NIH) awarded Lawrence ... develop an electrode array system that will enable ... through unprecedented resolution and scale. , LLNL,s grant-funded ... President Obama,s BRAIN (Brain Research through Advancing ... to revolutionize our understanding of the human mind ...
(Date:9/30/2014)... team of environmental scientists and engineers, led by ... a three-year, $5.25 million grant from the U.S. ... Research to make a direct positive impact on ... and disposal of radioactive contaminants. , "Understanding the ... dealing with environmental aspects of nuclear technologies is ...
Breaking Biology News(10 mins):Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2
... -- Several members of the American Society of Plant ... associates of the U.S. National Academy of Sciences in ... research. Three current ASPB members were elected to ... Curators Professor of Biological Sciences, University of MissouriColumbia ...
... French . Montreal May 4, 2011 ... may soon hit the market, thanks to an innovative study ... (MUHC). Their findings have characterized a unique biochemical diagnosis, which ... the month,s issue of the Journal of Alzheimer,s Disease ...
... piece to the obesity puzzle, showing how and why a ... the brain contributes to weight gain. This research appeared today ... and his team in the Institute,s Molecular Genetics Department made ... engineered to lack this protein, called protein tyrosine phosphatase epsilon ...
Cached Biology News:Blood test for Alzheimer's 2Weizmann Institute scientists discover: A protein that contributes to obesity 2
... Normal Pooled Human Serum • Human ... who are found to be negative by ... (s) (HIV-1Ag), Antibodies to Human Immunodeficiency Virus ... Nonreactive for Hepatitis B Surface Antigen (HbsAg) ...
... Molecular Imaging Systems offer an optional ... science researchers to conveniently capture and ... organs and whole animals with molecular ... of molecular signals that are generated ...
...
... Features hardwall acrylic panels mounted ... to form a free-standing modular ... Class 10/ISO 3. Optional ceiling ... ionizers are configured to customer ...
Biology Products: